Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • First Defense® Tri-Shield and First Defense for Scours
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • First Defense® Tri-Shield and First Defense for Scours
    • Testimonials
  • Re-Tain
    • Re-Tain™ for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
  • Resources
  • News
  • Investors
STOCK QUOTE
PRESS RELEASES

Recent News | 2018 | 2017 | 2016 | 2015 | 2014

SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

Recent News

2019  |  2018  |  2017  |  2016  |  2015  |  2014

11-11-19 ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

11-05-19 ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

09-17-19 ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

09-11-19 ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

08-29-19 ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

08-12-19 ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

08-06-19 ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019

05-13-19 ImmuCell Announces Unaudited Financial Results for First Quarter of 2019

05-07-19 ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019

03-29-19 ImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock

03-27-19 ImmuCell Corporation Announces Pricing of $9.0 Million Public Offering of Common Stock

03-26-19 ImmuCell Corporation Announces Commencement of Public Offering of Common Stock

02-28-19 ImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product

02-13-19 ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018

02-06-19 ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700
Contact Us

56 Evergreen Drive
Portland, ME 04103

Office: 207.878.2770
Sales: 1.800.IMMUCELL
mail@immucell.com

NASDAQ: ICCC

Privacy Policy

Terms of Use

Recent News

11-11-19 ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

11-05-19 ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

09-17-19 ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

09-11-19 ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

Follow Us

Find us on:

FacebookYouTube
Copyright © 2019 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales & Distributors
  • Resources
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top